Peroxisome Biogenesis Disorder 3A (Zellweger) — Comprehensive Research Report

Executive Summary

Peroxisome Biogenesis Disorder 3A (Zellweger) [PBD3A] is the severe, "classic" end of the Zellweger Spectrum Disorder (ZSD) continuum caused by biallelic pathogenic variants in PEX12 (peroxisomal biogenesis factor 12), corresponding to complementation group 3 (CG3) of the peroxisome biogenesis disorders. PEX12 encodes a RING-domain zinc-finger peroxisomal membrane E3 ubiquitin ligase that is a core structural component of the PEX2–PEX10–PEX12 retrotranslocation channel, which recycles the matrix-protein import receptor PEX5 across the peroxisomal membrane. Loss of PEX12 function abolishes peroxisomal matrix protein import, producing empty peroxisomal membrane "ghosts" and a systemic biochemical signature of accumulated very-long-chain fatty acids (VLCFA), phytanic/pristanic acid, and bile-acid intermediates, together with deficient plasmalogens and docosahexaenoic acid (DHA). Clinically this produces the classic cerebro-hepato-renal phenotype: profound neonatal hypotonia, seizures, distinctive craniofacial dysmorphism, neuronal migration defects (perisylvian polymicrogyria), hepatomegaly/liver dysfunction, renal cortical cysts, chondrodysplasia punctata, and early death (usually within the first year of life) in the classic/severe presentation — while other PEX12 genotypes produce milder, longer-surviving phenotypes across the ZSD continuum (OMIM #614859).

Note on nomenclature: the query template header listed "PEX2" alongside "PBD3A"; this is a common point of confusion. OMIM #614859 (PBD3A, Zellweger) is specifically the PEX12-caused disorder (complementation group 3). PEX2 mutations cause a genetically distinct, molecularly related disorder — PBD5A/5B (complementation group 10, formerly PBD2). Both genes encode paralogous RING-peroxin subunits of the same retrotranslocation channel, so the shared mechanistic biology below is directly informative for PEX2-caused disease, but the PBD3A identifier and the genetic/epidemiologic specifics below refer to PEX12.

1. Disease Information

Overview. Zellweger spectrum disorder (ZSD), historically divided into Zellweger syndrome (most severe), neonatal adrenoleukodystrophy (NALD, intermediate), and infantile Refsum disease (IRD, mildest), is now recognized as a single clinical continuum of peroxisome biogenesis disorders (PBDs) caused by biallelic pathogenic variants in any of at least 13 PEX genes required for peroxisome assembly and matrix-protein import (GeneReviews, NBK1448). PBD3A/Zellweger is the PEX12-caused, classically most severe subtype.

Key identifiers: - OMIM (phenotype): #614859 — Peroxisome Biogenesis Disorder 3A (Zellweger); PBD3A (OMIM) - OMIM (gene): 601758 — PEX12 - MONDO: MONDO:0013927 - DOID: DOID:0080478 - Orphanet: ORPHA:912 (Zellweger syndrome, umbrella entry); PEX12 gene page at Orphanet - HGNC: HGNC:8854 (PEX12); Entrez Gene ID 5193; Ensembl ENSG00000108733; UniProtKB O00623 - Chromosome location: 17q12 (GRCh38: 17:35,574,795–35,578,571) - ICD-10:* E71.510 (Zellweger syndrome)

Synonyms: Zellweger syndrome, complementation group 3 (CG3); cerebrohepatorenal syndrome (PEX12-related); PEX12-related Zellweger spectrum disorder; classic Zellweger syndrome.

Data provenance: Information is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) synthesizing case series, cohort studies, and molecular/cell-biology literature — not a single EHR-derived cohort. GeneReviews (Steinberg, Raymond, Braverman, Moser — updated periodically; NBK1448) is the most current clinically curated synthesis.

2. Etiology

Disease causal factor: Autosomal recessive, purely genetic. Biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic pathogenic variants in PEX12 abolish or reduce PEX12's function within the PEX2–PEX10–PEX12 peroxisomal retrotranslocation channel, causing failure of PTS1/PTS2-mediated peroxisomal matrix protein import and, in the severe/null genotype, near-total absence of morphologically and biochemically functional peroxisomes.

Genetic risk factors: - Causal biallelic PEX12 variants (nonsense, frameshift, splice-site, large deletion, and missense) — ClinGen classifies the PEX12–peroxisome biogenesis disorder (Zellweger spectrum) relationship as Definitive (ClinGen Peroxisomal GCEP; GenCC). - A founder mutation has been reported among Egyptian patients (PMID: 33123925), consistent with consanguinity-driven regional enrichment typical of autosomal recessive PBDs. - No modifier genes for PEX12-ZSD specifically have been characterized in the literature reviewed, though a well-documented allelic-expression-imbalance exception exists for PEX6 p.Arg860Trp (pseudo-dominant inheritance) — this does not apply to PEX12.

Genotype-phenotype relationship: The classic study by Chang et al. (Am J Hum Genet, 1998; PMID: 9792857) established a "relatively straightforward relationship between genotype and phenotype" in CG3: complete loss of PEX12 function produces more-severe cellular and clinical phenotypes, and this holds across the PBD3A/PBD3B split in OMIM (severe #614859 "3A" vs. milder #266510 "3B"). A notable exception was a compound-heterozygote patient with two apparently severe alleles who showed a mild phenotype because translation reinitiation at a downstream AUG codon produced a partially functional 29-kD truncated protein — illustrating that apparent variant severity at the DNA level does not always predict protein-level residual function.

Risk factors — environmental/lifestyle: None identified; this is a purely monogenic disorder with no known environmental, infectious, or lifestyle contribution to occurrence. Prenatal environmental exposures do not modify penetrance (fully penetrant when biallelic null variants are present).

Protective factors: No genetic or environmental protective factors are documented for PEX12-ZSD; disease severity is determined almost entirely by residual PEX12 protein function from the specific allele combination.

Gene-environment interactions: Not applicable/not reported — ZSD is not known to involve meaningful gene-environment interaction; it is a cell-autonomous organelle-biogenesis defect.

3. Phenotypes

Phenotype data are aggregated primarily from GeneReviews, StatPearls (PMID/NBK560676), a systematic scoping review/meta-analysis of clinical findings (Klouwer et al./Waterham lab work; MDPI 2022, PMC9221082), and classic Zellweger descriptions. Severity and onset vary across the ZSD continuum; PBD3A (severe/"3A" designation) corresponds to the classic neonatal-onset, rapidly fatal presentation.

Severity/progression: Severe (PBD3A-classic) ZSD presents neonatally and is generally fatal within the first year, predominantly from respiratory compromise, without developmental progress. Intermediate/milder genotypes (including hypomorphic PEX12 alleles) may not manifest fully until later infancy/childhood, follow a progressive sensorineural (hearing/vision) decline, and — per GeneReviews — children surviving the first year with a non-progressive neurologic course have a 77% probability of reaching school age, with some attaining normal intellect.

Quality of life impact: Severe form: profound, terminal — essentially no meaningful developmental trajectory. Milder survivors: substantial cumulative burden from progressive deafness, blindness, hepatic disease, and skeletal/dental complications, but some individuals attend regular school with good reported quality of life under treatment (cholic acid cohorts; PMC6062720).

4. Genetic/Molecular Information

Causal gene: PEX12 (HGNC:8854; OMIM *601758; Entrez 5193; chr17q12; GRCh38:17:35,574,795-35,578,571).

Protein: Peroxisomal biogenesis factor 12 (PEX12p), a 359-amino-acid integral peroxisomal membrane protein with an N-terminal cytoplasmic domain, two transmembrane segments, a peroxisomal matrix-facing loop, and a C-terminal cysteine-rich C3HC4 zinc RING finger E3 ubiquitin ligase domain (Okumoto et al., Mol Cell Biol 1998; PMID: 9632816).

Discovery/original complementation group naming: PEX12 was cloned by functional complementation of the peroxisome-deficient CHO mutant cell line ZP109 and shown to complement fibroblasts from complementation group III (CG-III) Zellweger patients, establishing PEX12 as the CG3 pathogenic gene (Okumoto 1998, above).

Pathogenic variant spectrum: - Nonsense, frameshift, splice-site, and large deletion variants → complete loss of function → most severe (classic PBD3A) phenotype. - Missense variants and variants permitting downstream translation reinitiation (e.g., a truncated 29-kD PEX12 protein retaining partial activity) → milder phenotypes (Chang et al. 1998, PMID: 9792857). - Novel PEX12 mutations continue to be reported across populations, including a mild-phenotype allele with mosaic catalase immunofluorescence at 40°C (J Hum Genet, Nature link) and additional novel variants (Eur J Hum Genet, PMID: 14571262). - A founder mutation in the Egyptian population has been characterized (PMID: 33123925). - ACMG/AMP classification: Loss-of-function variants are classified pathogenic; large deletions, nonsense, and frameshift variants are consistently the most severe class.

Allele frequency: PEX12 accounts for approximately 7.6% of molecularly solved ZSD cases (GeneReviews Table 2), making it the third most common ZSD gene after PEX1 (~60.5%) and PEX6 (~14.5%). Population-level carrier frequency data specific to PEX12 were not identified in gnomAD-focused searches within this review; general ZSD carrier frequency is consistent with the disorder's overall birth prevalence (see Section 9).

Somatic vs. germline: Exclusively germline; no somatic mosaicism reports beyond the noted catalase-mosaic cellular phenotype (a cell-biological readout of variable expressivity, not somatic mosaicism per se).

Functional consequence: Loss of function (complete or partial) of PEX12's E3 ubiquitin ligase / channel-structural role. No gain-of-function or dominant-negative PEX12 alleles are reported; inheritance is strictly autosomal recessive/biallelic.

Modifier genes: None specifically documented for PEX12; broader ZSD literature notes complex genotype-phenotype relationships are gene- and allele-specific rather than governed by known trans-acting modifiers.

Chromosomal abnormalities: Not a mechanism in this disorder — PBD3A arises from intragenic PEX12 variants, not aneuploidy or gross structural rearrangement (though large deletions of PEX12 have been reported as one class of severe variant).

Epigenetics: No disease-specific epigenetic mechanism has been characterized for PEX12-ZSD in the literature surveyed.

5. Environmental Information

No environmental toxin, occupational exposure, infectious agent, or lifestyle factor is causally implicated in PBD3A — it is a fully penetrant monogenic disorder. There are no known gene-environment interactions modulating expressivity in the literature reviewed.

6. Mechanism / Pathophysiology

Causal chain overview: biallelic PEX12 loss-of-function → disrupted PEX2–PEX10–PEX12 retrotranslocation channel assembly → failure of PEX5 receptor export/recycling → collapse of peroxisomal matrix protein import → absence of functional peroxisomal matrix enzymes despite persistence of "peroxisomal ghost" membranes → systemic accumulation of peroxisomally-metabolized substrates and deficiency of peroxisomally-synthesized lipids → multi-organ toxicity (CNS, liver, kidney, adrenal, skeletal, sensory).

Molecular pathway — the PEX2-PEX10-PEX12 retrotranslocation channel: PEX2, PEX10, and PEX12 are paralogous RING-type zinc-finger peroxins that co-assemble in the peroxisomal membrane into a channel with an ~10 Å open pore, with the RING zinc fingers positioned cytosolically above the pore (Skowyra & Rapoport et al., Nature 2022, "A peroxisomal ubiquitin ligase complex forms a retrotranslocation channel"; also PNAS 2010, "Different functions of the C3HC4 zinc RING finger peroxins PEX10, PEX2, and PEX12 in peroxisome formation and matrix protein import"). Mechanistically: - PEX2 monoubiquitinates the PTS1-receptor PEX5 at Cys11, enabling PEX5 recycling for continued rounds of matrix protein import. - When recycling is impaired, PEX10 polyubiquitinates PEX5, targeting it for proteasomal degradation. - PEX12 is a core structural/regulatory component of this same channel and stimulates PEX10's ligase activity, ensuring regulated PEX5 turnover — the specific mechanistic role disrupted in PBD3A.

Cellular process disrupted: peroxisomal matrix protein import (GO:0016558, protein import into peroxisome matrix); ubiquitin-dependent protein catabolic process at the peroxisomal membrane (GO:0016567 ubiquitination-related). Loss of PEX12 abolishes this translocon function; residual "peroxisomal ghosts" (PEX12-null cells still form membrane structures but cannot import matrix enzymes) are seen morphologically.

Biochemical abnormalities (the diagnostic signature): - Accumulation of very-long-chain fatty acids (VLCFA, esp. C26:0 and C26:1), phytanic acid, pristanic acid, and C27 bile-acid (di- and trihydroxycholestanoic acid, DHCA/THCA) intermediates — normally beta-oxidized/processed in the peroxisomal matrix. - Deficiency of plasmalogens (ether phospholipids essential for myelin) and docosahexaenoic acid (DHA), normally synthesized in peroxisomes. - Elevated pipecolic acid.

Tissue damage mechanisms: - CNS: Peroxisomal dysfunction during fetal cortical development impairs neuronal precursor migration, producing the perisylvian polymicrogyria/pachygyria characteristic of Zellweger syndrome; the PEX2 mouse model (a mechanistically analogous RING-peroxin knockout) directly demonstrated delayed neuronal migration in the cerebral cortex via in vivo mitotic labeling (Faust & Hatten, J Cell Biol 1997; PMID: 9382874), plus abnormal cerebellar histogenesis reflecting multiple neuronal defects from peroxisome deficiency. - Liver: VLCFA and C27 bile-acid intermediate accumulation is directly hepatotoxic and drives progressive fibrosis/cholestasis. - Adrenal cortex: VLCFA accumulation in adrenocortical cells impairs steroidogenesis, reducing ACTH-responsive cortisol output and causing adrenal insufficiency. - Kidney: Renal cortical cyst formation (mechanism less well characterized mechanistically but consistently observed). - Lipid/cholesterol homeostasis: PEX2 knockout mice show disturbed cholesterol homeostasis (PMID: 14673138), illustrating broader lipidomic disruption beyond VLCFA/plasmalogen handling — directly relevant as PEX2 is a paralogous channel subunit.

Suggested ontology terms: - GO (biological process): GO:0016558 (protein import into peroxisome matrix); GO:0007031 (peroxisome organization); GO:0006636 (unsaturated fatty acid biosynthesis, for plasmalogen-adjacent pathways); GO:0033539 (fatty acid beta-oxidation using acyl-CoA oxidase) - GO (molecular function): GO:0004842 (ubiquitin-protein transferase activity); GO:0008270 (zinc ion binding) - GO (cellular component): GO:0005778 (peroxisomal membrane); GO:0005782 (peroxisomal matrix) - CL: CL:0000540 (neuron), CL:0000601 (radial glial cell — for migration mechanism), CL:0000182 (hepatocyte), CL:0001133 (adrenal cortex cell) - CHEBI: CHEBI:143092 or specific VLCFA entries (hexacosanoic acid, C26:0); CHEBI:28865 (phytanic acid); CHEBI:36620 (cholic acid)

7. Anatomical Structures Affected

Organ level (primary): Brain/CNS, liver, kidney (the classic "cerebro-hepato-renal" triad), adrenal gland, eye, inner ear, skeleton (epiphyses/patella).

Organ level (secondary/complications): Cardiovascular defects (reported), gastrointestinal (feeding dysfunction), dental (enamel).

Body systems: Nervous, hepatobiliary, renal, endocrine, skeletal, special sensory (auditory, visual), integumentary/dental.

Tissue/cell level: - Cerebral cortex — neuronal migration/lamination defect (perisylvian region especially) - Cerebellum — abnormal histogenesis - Hepatocytes — fibrosis, cholestasis - Renal cortex — cystic epithelium - Adrenal cortex — steroidogenic cell dysfunction - Retinal photoreceptors — pigmentary retinopathy - Cochlear hair cells — sensorineural hearing loss - Epiphyseal cartilage/chondrocytes — chondrodysplasia punctata

Subcellular level: The disease is fundamentally a peroxisomal-membrane/matrix lesion — peroxisomal membrane (GO:0005778, site of the defective PEX2-PEX10-PEX12 channel) and peroxisomal matrix (GO:0005782, site of failed enzyme import). Downstream effects also implicate mitochondria (bizarre/enlarged mitochondrial inclusions reported in muscle of PEX12- and PEX16-mutant patients) and myelin/ER-related lipid synthesis machinery (plasmalogen deficiency).

Localization/laterality: CNS lesions (polymicrogyria) are typically bilateral and regionally localized to the perisylvian/opercular cortex; renal cysts are bilateral cortical; hepatomegaly and adrenal involvement are systemic/bilateral by nature.

Suggested UBERON terms: UBERON:0000955 (brain), UBERON:0002107 (liver), UBERON:0002113 (kidney), UBERON:0002369 (adrenal gland), UBERON:0000970 (eye), UBERON:0001846 (inner ear), UBERON:0001981 (blood vessel — for skeletal patellar involvement region), UBERON:0009834 (perisylvian cortex-adjacent region if available).

8. Temporal Development

Onset: Congenital/prenatal biochemical defect; clinical onset is neonatal in the classic PBD3A/severe form. Milder PEX12 genotypes may present later in infancy or childhood, primarily via developmental delay, hearing loss, or visual impairment rather than acute neonatal crisis.

Onset pattern: Acute/severe in classic disease (present at or shortly after birth); insidious/progressive in intermediate-mild disease.

Progression: - Severe: static-to-declining neurologic status from birth; death typically within the first year, usually from respiratory failure; no developmental progress achieved. - Intermediate/mild: progressive sensory decline (hearing, vision), possible late-onset leukodystrophy with regression/loss of previously acquired skills; hepatic and renal manifestations may evolve over years.

Disease course pattern: Progressive (not typically relapsing-remitting); no spontaneous remission is described. Course is chronic and lifelong in survivors, with cumulative multi-organ morbidity.

Critical periods: The prenatal/early postnatal window is a critical period for neuronal migration — because peroxisomal function is required during a fixed developmental window for cortical lamination, migration defects (polymicrogyria) are fixed structural lesions not amenable to later correction, unlike some progressive elements (hearing, liver) that are more amenable to surveillance-based intervention.

9. Inheritance and Population

Epidemiology: - Estimated ZSD birth incidence in North America: 1 in 50,000 to 1 in 75,000 live births (varies by source); StatPearls cites ~1:50,000. - Regional variation: Quebec ~1:12,000 (founder effect); Japan ~1:500,000 (much lower); a New York newborn-screening-derived estimate suggests 1:133,000. - PEX12 specifically accounts for ~7.6% of molecularly diagnosed ZSD cases (GeneReviews). - A 2025 population-genetics modeling study (PMC12166394 / gimopen.org) estimated conservative PEX1-mediated ZSD prevalence at roughly 500 total patients across the US, UK, Germany, France, Italy, Spain, and Japan combined — and specifically flagged that a substantial fraction of intermediate/mild-phenotype patients (which would include some milder PEX12 genotypes) likely go unrecognized by current diagnostic practice, implying true prevalence for all ZSD genes (including PEX12) is underestimated.

Inheritance pattern: Autosomal recessive (biallelic PEX12 pathogenic variants required).

Penetrance: Complete/full penetrance for biallelic loss-of-function genotypes; expressivity (not penetrance) varies with residual PEX12 activity.

Expressivity: Highly variable, genotype-correlated (see Section 4) — ranging from lethal neonatal disease to long-term survival with sensory/hepatic morbidity.

Genetic anticipation: Not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically reported for PEX12 in the literature surveyed; standard recurrence risk counseling (25% recurrence per sibship) applies.

Founder effects: A PEX12 founder mutation has been documented in the Egyptian population (PMID: 33123925), consistent with a broader pattern of PEX-gene founder alleles in consanguineous populations (analogous to the well-known PEX1 founder effects in Quebec/French-Canadian populations that drive that region's elevated ZSD incidence).

Consanguinity: A significant contributor, as for essentially all severe autosomal recessive PBDs — increases the probability of biallelic PEX12 variant co-inheritance in populations/families with elevated consanguinity rates.

Carrier frequency: Not specifically quantified for PEX12 in the sources reviewed; population-specific carrier screening panels for ZSD typically include PEX12 alongside PEX1/PEX6/PEX10/PEX26.

Population demographics/geography: No specific ethnic predisposition beyond founder-effect populations (Egyptian PEX12 founder mutation; broader ZSD founder effects in French-Canadian/Quebec, and lower incidence in Japan). Sex ratio: no sex predilection reported (autosomal recessive). Age distribution: neonatal-to-early-childhood presentation predominates given disease severity, though survivors are followed into adulthood.

10. Diagnostics

Biochemical/laboratory tests: - Plasma VLCFA panel (elevated C26:0, C26:1, elevated C24:0/C22:0 and C26:0/C22:0 ratios) — first-line biochemical screen. - Plasma phytanic and pristanic acid (elevated). - Plasma/urine bile acid intermediates (elevated DHCA, THCA). - RBC plasmalogen levels (decreased — C16 and C18 plasmalogens). - Pipecolic acid (elevated). - C26:0-lysophosphatidylcholine (C26:0-LPC) in dried blood spot by LC-MS/MS — an emerging, sensitive biomarker validated for both diagnostic workup and potential newborn screening for ZSD (PMC10910329; Springer 2017 diagnostic-markers study). - Note: mild/intermediate cases may show normal biochemical screening, necessitating molecular testing when clinical suspicion is high.

Imaging: Brain MRI — perisylvian/opercular polymicrogyria or pachygyria, periventricular neuronal heterotopia, poor myelination/hypomyelination, progressive leukodystrophy in survivors. Renal ultrasound — cortical cysts. Skeletal radiographs — chondrodysplasia punctata (stippled epiphyses, especially patella).

Genetic testing: - Multigene ZSD/PEX panel (first-line given genetic heterogeneity across 13+ PEX genes) or exome/genome sequencing. - PEX12 sequence-variant detection rate: 19/22 to 43/43 depending on cohort (near-complete sensitivity by sequencing per GeneReviews Table 2). - Complementation testing (historical/research method — fibroblast fusion assays defining CG3) has been largely superseded by molecular sequencing but remains conceptually important (it is how PEX12 was originally identified as the CG3 gene). - Prenatal/preimplantation genetic testing available once familial variants are known.

Clinical criteria: No formal DSM/ICD diagnostic algorithm beyond clinical recognition + biochemical/molecular confirmation; diagnosis requires biallelic pathogenic PEX12 (or other ZSD-PEX gene) variants combined with compatible clinical/biochemical findings (GeneReviews).

Differential diagnosis: Other peroxisomal disorders (X-linked adrenoleukodystrophy, acyl-CoA oxidase deficiency, D-bifunctional protein deficiency, rhizomelic chondrodysplasia punctata type 1/PEX7); non-peroxisomal etiologies of neonatal hypotonia, hepatomegaly, and dysmorphism (congenital disorders of glycosylation, mitochondrial disorders, other causes of hereditary hearing loss/retinal dystrophy/Usher syndrome, other leukodystrophies).

Screening: Newborn screening for ZSD via C26:0-lysoPC (piggybacking on existing X-ALD newborn screening infrastructure in several US states) is increasingly implemented and can identify ZSD cases including PEX12-caused disease pre-symptomatically.

Suggested NCIT/LOINC context: LOINC panels exist for plasma VLCFA and bile-acid-intermediate profiling; specific LOINC codes were not individually resolved in this search pass and should be verified against LOINC directly during curation.

11. Outcome/Prognosis

Survival/mortality: Classic/severe (PBD3A) ZSD: death typically within the first year of life, most commonly from respiratory compromise, with no significant developmental progress achieved. Intermediate/mild genotypes: substantially prolonged survival; per GeneReviews, children with a non-progressive course who survive infancy have a 77% probability of reaching school age.

Morbidity/function: Progressive sensorineural hearing loss and retinal degeneration are major contributors to lifelong disability in survivors; hepatic dysfunction, adrenal insufficiency, and renal complications (nephrolithiasis) add cumulative multi-system morbidity. Some intermediate-phenotype adults have been identified with predominantly sensory deficits and normal neurologic development, representing the mildest end of the spectrum.

Complications: Progressive leukodystrophy (loss of previously acquired skills) in a subset of milder survivors; adrenal crisis if insufficiency is undiagnosed/untreated; hepatic fibrosis progression; renal calcium-oxalate stone disease; enamel/dental complications.

Prognostic factors: Genotype (residual PEX12 function) is the dominant prognostic determinant (Section 4); early diagnosis and initiation of supportive/adjunctive therapy (e.g., cholic acid) is associated with stabilized liver function and improved functional outcomes in surviving patients (long-term cholic acid cohort: stabilized liver function, no treatment-related adverse effects, all three followed patients attended regular school; PMC6062720).

12. Treatment

There is no curative or disease-modifying therapy that restores peroxisome biogenesis; management is supportive/symptomatic plus one FDA-approved adjunctive pharmacotherapy targeting a specific downstream biochemical consequence.

Pharmacotherapy: - Cholic acid (Cholbam®) — FDA-approved March 2015, the only approved adjunctive therapy for ZSD-associated bile acid synthesis disorders. Mechanism: oral cholic acid restores physiologic FXR-mediated negative feedback inhibition of endogenous bile acid synthesis, thereby suppressing the hepatotoxic C27 bile-acid intermediates (DHCA/THCA) that accumulate due to peroxisomal beta-oxidation failure (PMC5065608, PMC8439061, PMC6062720). Long-term cohort data show stabilized liver function without treatment-related adverse effects, though patients with already-advanced liver disease may show increased transaminases/bilirubin with only minor reduction in intermediates. - NCIT: NCIT:C15986 (Pharmacotherapy); therapeutic_agent: CHEBI:36620 (cholic acid) or NCIT drug-specific code. - Docosahexaenoic acid (DHA) supplementation — trialed given low endogenous DHA; randomized controlled trials did not show improved neurological or visual outcomes, so it is not an established disease-modifying therapy despite biological plausibility. - Fat-soluble vitamin supplementation (A, D, E, K) — supportive, addressing malabsorption/hepatic dysfunction-related deficiency. - Adrenal replacement therapy (hydrocortisone) — for documented adrenal insufficiency. - Anti-seizure medications — symptomatic seizure control.

Surgical/interventional: Gastrostomy tube placement for feeding difficulty (NCIT:C15329, Surgical Procedure, or a more specific NCIT gastrostomy term).

Supportive/rehabilitative: - Hearing aids / cochlear implantation consideration for sensorineural hearing loss. - Visual correction / low-vision services for retinopathy. - Physical/occupational therapy (NCIT:C15302 Physical Therapy). - Dental intervention for amelogenesis imperfecta (6-month surveillance). - Management of renal oxalate stones.

Experimental: No PEX12-specific gene therapy or targeted molecular therapeutic is in active clinical trials per the sources reviewed (searches for Zellweger clinical trials returned only cholic acid/DHA studies as the notable interventional trials; no specific NCT identifiers for gene-replacement approaches in PEX12-ZSD were surfaced in this pass and should be re-verified directly against ClinicalTrials.gov during curation).

Surveillance protocol (GeneReviews): annual audiology and ophthalmology evaluation; liver function monitoring (ultrasound/fibroscan); adrenal function (ACTH/cortisol) assessment beginning at age 1 year then annually; dental exams every 6 months; annual urine oxalate-to-creatinine ratio; ongoing developmental assessment.

Treatment algorithm: Management is multidisciplinary and symptom-directed rather than a single algorithm — metabolic/genetics, hepatology, endocrinology, audiology, ophthalmology, neurology, and dentistry each contribute organ-specific surveillance and intervention per the schedule above.

13. Prevention

Primary prevention: Not possible in the traditional sense (no modifiable risk factor); the only "primary prevention" avenue is genetic — carrier screening and reproductive counseling in at-risk families/populations (especially those with known founder mutations or elevated consanguinity), and prenatal diagnosis/preimplantation genetic testing once familial PEX12 variants are identified.

Secondary prevention (early detection): Newborn screening via C26:0-lysoPC dried-blood-spot analysis is increasingly implemented in some jurisdictions (originally built for X-ALD screening) and can identify ZSD cases — including PEX12-caused disease — presymptomatically, enabling earlier surveillance and adjunctive treatment initiation.

Tertiary prevention: The structured surveillance program above (Section 12) functions as tertiary prevention, aiming to catch and manage complications (adrenal crisis, hepatic decompensation, hearing/vision loss progression, nephrolithiasis) before they cause irreversible additional morbidity.

Genetic counseling: Central to prevention in this autosomal recessive disorder — each sibling of an affected individual has a 25% recurrence risk, 50% carrier probability, and 25% unaffected/non-carrier probability; carrier testing is available once familial variants are identified; prenatal and preimplantation genetic testing are offered to at-risk couples.

Public health/screening programs: No vaccination or infectious-prevention component (not an infectious disease). The main public-health lever is expansion of newborn screening programs incorporating C26:0-lysoPC alongside existing X-ALD screening infrastructure, and population-specific carrier screening in communities with known founder alleles (e.g., Egyptian PEX12 founder mutation).

14. Other Species / Natural Disease

Taxonomy: No naturally occurring PEX12-specific disease has been reported in non-human species in the literature surveyed; PEX12 orthologs exist broadly across eukaryotes given the conserved essential role of peroxisome biogenesis (NCBITaxon:9606 for human; mouse ortholog below).

Gene orthologs: Mouse Pex12 (MGI:2144177); no naturally-occurring veterinary PEX12-deficiency disease (e.g., in companion animals) was found in this search — unlike some other inherited metabolic diseases, PBD3A does not appear to have a well-characterized spontaneous veterinary counterpart in OMIA in the sources reviewed.

Comparative biology: The PEX2-PEX10-PEX12 retrotranslocation channel and PEX5 ubiquitination/recycling mechanism is evolutionarily conserved from yeast to humans (the original functional-complementation cloning of PEX12 exploited cross-species/cross-cell-line conservation — rat PEX12 cDNA complemented a CHO cell peroxisome-deficiency mutant and human CG-III patient fibroblasts), underscoring deep conservation of this pathway.

15. Model Organisms

Mouse: - A dedicated constitutive Pex12 knockout mouse with detailed published phenotyping was not identified in this search pass; MGI (MGI:2144177) and IMPC list the gene but with limited reported phenotype data ("0 significant phenotypes reported... across 24 physiological systems" per IMPC summary retrieved) — this is a gap worth flagging for curation (i.e., PEX12 mouse-model data may be sparse/unpublished relative to other PEX genes). - The most directly informative mouse model for the shared mechanistic biology of this RING-peroxin complex is the PEX2 knockout mouse (Faust & Hatten, J Cell Biol 1997; PMID: 9382874): homozygous PEX2-null mice survive gestation but die within hours of birth, are hypoactive, markedly hypotonic, and fail to feed; they assemble peroxisomal membrane "ghosts" without functional matrix import, accumulate VLCFA, are plasmalogen-deficient, and show delayed neuronal migration in the cerebral cortex (demonstrated via in vivo mitotic-marker labeling) and abnormal cerebellar histogenesis reflecting combined migration/proliferation/differentiation/survival defects. A related paper documents disturbed cholesterol homeostasis in this PEX2-knockout model (PMID: 14673138). - The Pex1-G844D (p.Gly844Asp) hypomorphic mouse is the most extensively used model for milder ZSD, with recent (2024-2025) studies characterizing longitudinal liver disease progression and RPE structural/lipid changes (biorxiv preprints) — relevant as a phenotyping template even though it is PEX1- not PEX12-specific. - Other ZSD-adjacent murine models: Pex7-deficient mice (rhizomelic chondrodysplasia punctata type 1 model; PMC9310236), Pex11a-deficient mice (mild peroxisomal dysfunction, dyslipidemia/obesity phenotype — a different, non-Zellweger PEX11 mechanism).

Zebrafish: Zebrafish pex12 ortholog (accession B0R157) has been characterized in the peroxisomal protein inventory (Frontiers 2022, PMC/fphys.2022.822509), but a dedicated pex12 loss-of-function zebrafish disease-model paper was not surfaced in this search; a pex1 loss-of-function zebrafish model was recently published (2025) as viable and recapitulating ZSD hallmarks (PMC12626956), suggesting zebrafish PEX12 modeling is a plausible near-term/emerging resource but not yet as established.

Drosophila: Pex12 (FlyBase FBgn0031282) — described as important for sperm development in the fly, distinct from the vertebrate multi-organ phenotype; Drosophila models of Pex3/Pex16 mutation (PMC3149631) have been established as ZSD models and are the most-published fly models in this pathway, again illustrating that most published invertebrate ZSD modeling to date centers on other PEX genes rather than PEX12 specifically.

Model limitations: Across the PEX-complex model literature, murine PEX2/PEX1 knockouts recapitulate neonatal lethality, hypotonia, VLCFA accumulation, and neuronal migration defects well, but do not fully recapitulate the human sensorineural/retinal progressive phenotype seen in milder human ZSD survivors (a HUMAN_MODEL_MISMATCH-type gap, since the severe mouse models die too early to model the progressive sensory decline that defines intermediate human ZSD, and dedicated PEX12 mouse phenotyping data appear comparatively sparse in the literature surveyed).

Applications: These models have been used to study neuronal migration/cortical lamination mechanisms, lipid/cholesterol homeostasis disruption, cerebellar histogenesis, and (in the Pex1-G844D model) longitudinal liver and retinal pigment epithelium disease progression — directly informing the pathophysiology causal-chain content above.

Curation Notes / Flagged Gaps for the KB Entry

1. Nomenclature disambiguation is essential: the entry should clearly state PBD3A = PEX12 (complementation group 3), distinct from PEX2-caused disease (PBD5A/5B, complementation group 10) despite the template header's ambiguity — the mechanistic/molecular-pathway material (PEX2-PEX10-PEX12 channel) is shared and should be cited generically, but gene-specific genetic/epidemiologic claims (Section 4, 9) are PEX12-specific and must not be attributed to PEX2 evidence sources without noting the cross-paralog inference.
2. Several PEX2-mouse-model citations (Faust & Hatten 1997; PMID 14673138) are being used as MODEL_ORGANISM evidence for the shared retrotranslocation-channel mechanism, not as direct PEX12 evidence — flag evidence_source: MODEL_ORGANISM and consider a HUMAN_MODEL_MISMATCH-style note that a dedicated PEX12 murine phenotype dataset is comparatively thin in the literature surveyed here and should be re-searched directly in MGI/IMPC before final curation.
3. Verify current NCT identifiers directly against ClinicalTrials.gov — this search pass surfaced only historical cholic acid/DHA trial literature, not currently active interventional trials specific to PEX12-ZSD.
4. LOINC codes for VLCFA/bile-acid-intermediate panels and precise CHEBI IDs for pristanic/phytanic acid/VLCFA species should be independently verified via OAK before binding, per dismech's term-validation workflow.

Sources

• OMIM #614859 — PBD3A (Zellweger)
• OMIM *601758 — PEX12
• GeneReviews: Zellweger Spectrum Disorder (NBK1448)
• StatPearls: Zellweger Spectrum Disorder (NBK560676)
• Okumoto et al. 1998, PEX12 cloning, PMID 9632816
• Chang et al. 1998, CG3 genotype-phenotype, PMID 9792857
• Novel PEX12 mutations, Eur J Hum Genet, PMID 14571262
• Egyptian PEX12 founder mutation, PMID 33123925
• Mild PEX12 mutation, mosaic catalase pattern, J Hum Genet
• ClinGen Peroxisomal Gene Curation Expert Panel evaluation
• GenCC PEX12 submissions
• Faust & Hatten 1997, PEX2 mouse model, PMID 9382874
• PEX2 knockout mouse cholesterol homeostasis, PMID 14673138
• Skowyra & Rapoport, retrotranslocation channel structure, Nature 2022
• Different functions of PEX10, PEX2, PEX12 in matrix protein import, PNAS 2010
• Cholic acid therapy in ZSD, PMC5065608
• Long-term cholic acid therapy, PMC6062720
• Cholbam and ZSD management, PMC8439061
• C26:0-lysoPC diagnostic biomarker, PMC10910329
• Characterization of Severity in ZSD, meta-analysis, MDPI 2022
• Estimation of PEX1-mediated ZSD population prevalence, 2025
• PEX13-related ZSD genotype-phenotype, PMC9295491
• PEX12 GeneCards
• PEX1 zebrafish model, PMC12626956
• Pex12 MGI Gene Detail
• MalaCards: Peroxisome Biogenesis Disorder 3A

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.